Companies: 10,795·Total market cap: $144.5T
Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co., Ltd.

SNPHYOTCHealthcare● Active
$12.15
+$0.40(+3.38%)
Market Cap$3.9B
P/E Ratio—
52W High$12.68
52W Low$9.22
Shares OutstandingFinancialsRevenue

Santen Pharmaceutical Co., Ltd. (SNPHY) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

SNPHY · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
327.6M▼ -6.02% YoY Change
FY · as of Mar 31, 2026 · Reported in JPY
vs 348.6M in FY 2025
Diluted Shares Outstanding
328.4M
incl. options, RSUs, convertibles
Dilution Spread
+0.23%
Diluted vs Basic
YoY Change
-6.02%
year-over-year
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRdeclining
-5.4%
2023 → 2026
5-Year CAGRdeclining
-3.9%
2021 → 2026
10-Year CAGRdeclining
-2.3%
2016 → 2026
ⓘ

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2026Latest
Diluted Shares: 328.4M
327.6M
-6.02%
FY 2025
Diluted Shares: 349.7M
348.6M
-4.98%
FY 2024
Diluted Shares: 368.1M
366.9M
-5.30%
FY 2023
Diluted Shares: 387.4M
387.4M
-3.09%
FY 2022
Diluted Shares: 400.5M
399.8M
+0.08%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs SNPHY
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+663.7%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+641.3%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+443.4%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+373.1%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+177.8%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+174.1%
#7
Santen Pharmaceutical Co., Ltd.SNPHY
Santen Pharmaceutical Co., Ltd.YOU
327.6M—

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Santen Pharmaceutical Co., Ltd. (SNPHY) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of March 31, 2026, Santen Pharmaceutical Co., Ltd. reports 327.6M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Santen Pharmaceutical Co., Ltd.'s basic shares outstanding (327.6M) represents currently issued shares. Diluted shares outstanding (328.4M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.23%.

Shares Outstanding vs. Float (Free Float)

Santen Pharmaceutical Co., Ltd.'s float is — (— of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · JPY

About shares outstanding & methodology

Santen Pharmaceutical Co., Ltd. (SNPHY) shares outstanding history from 2007 to 2026. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Santen Pharmaceutical Co., Ltd. shares outstanding for the fiscal year ending March 31, 2026 were 327.6M, a 6.02% decline year-over-year. Santen Pharmaceutical Co., Ltd. FY 2026 shares outstanding were 327.6M, a -6.02% decline from FY 2025.

Santen Pharmaceutical Co., Ltd. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of -2.3% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.
Market capSplitsEarningsFinancials (Income)Cash on handFree cash flowNet incomePrice history

Frequently asked questions

SNPHY shares outstanding · 4 questions

As of March 31, 2026, Santen Pharmaceutical Co., Ltd. (SNPHY) has approximately 327.6M basic shares outstanding and 328.4M diluted shares outstanding. This represents a -6.02% year-over-year change from FY 2025 (348.6M). Santen Pharmaceutical Co., Ltd.'s declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.

SNPHY shares outstandinghow many shares does SNPHY haveSNPHY basic shares 2026SNPHY diluted shares

▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Santen Pharmaceutical Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09